Kane Biotech OTC Stock Top Insiders
KNBIF Stock | USD 0.08 0 3.13% |
Kane Biotech employs about 18 people. The company is managed by 9 executives with a total tenure of roughly 22 years, averaging almost 2.0 years of service per executive, having 2.0 employees per reported executive. Examination of Kane Biotech's management performance can provide insight into the company performance.
Mark AhrensTownsend CEO President CEO |
Marc Edwards CEO Interim CEO, Director |
Kane |
Kane Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.3915) % which means that it has lost $0.3915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.968) %, meaning that it generated substantial loss on money invested by shareholders. Kane Biotech's management efficiency ratios could be used to measure how well Kane Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Kane Biotech Workforce Comparison
Kane Biotech is currently regarded as number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 25,628. Kane Biotech adds roughly 18.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (1.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.72. Kane Biotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Kane Biotech Price Series Summation is a cross summation of Kane Biotech price series and its benchmark/peer.
Kane Biotech Notable Stakeholders
A Kane Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kane Biotech often face trade-offs trying to please all of them. Kane Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kane Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark AhrensTownsend | President CEO | Profile | |
Marc Edwards | Interim CEO, Director | Profile | |
Kevin Cole | Pres Inc | Profile | |
Wendy Nachtigall | Director Marketing | Profile | |
Gregory Schultz | Chief Board | Profile | |
Lorne Gorber | Investor Relations | Profile | |
Ray Dupuis | Chief Officer | Profile | |
Nicole Sendey | Investor Adviser | Profile | |
Lori Christofalos | VP Compliance | Profile |
About Kane Biotech Management Performance
The success or failure of an entity such as Kane Biotech often depends on how effective the management is. Kane Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kane management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kane management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States.
The data published in Kane Biotech's official financial statements typically reflect Kane Biotech's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Kane Biotech's quantitative information. For example, before you start analyzing numbers published by Kane accountants, it's essential to understand Kane Biotech's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Kane Biotech Workforce Analysis
Traditionally, organizations such as Kane Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kane Biotech within its industry.Kane Biotech Manpower Efficiency
Return on Kane Biotech Manpower
Revenue Per Employee | 89.3K | |
Revenue Per Executive | 178.6K | |
Net Loss Per Employee | 255.8K | |
Net Loss Per Executive | 511.6K |
Complementary Tools for Kane OTC Stock analysis
When running Kane Biotech's price analysis, check to measure Kane Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kane Biotech is operating at the current time. Most of Kane Biotech's value examination focuses on studying past and present price action to predict the probability of Kane Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kane Biotech's price. Additionally, you may evaluate how the addition of Kane Biotech to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |